Calcium aluminium silicate - Salient Pharmaceuticals

Drug Profile

Calcium aluminium silicate - Salient Pharmaceuticals

Alternative Names: Aluminium calcium silicate; Aluminum calcium silicate; Calcium alumina-silicate; Calcium aluminosilicate; Calcium aluminosilicate anti-diarrheal; Calcium aluminosilicate anti-diarrhoeal - Salient Pharmaceuticals; Calcium aluminum silicate; Calcium silicoaluminate; CASAD; Silicate cement; Silicic acid aluminium calcium salt; Silicic acid aluminum calcium salt

Latest Information Update: 19 Apr 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Salient Pharmaceuticals
  • Developer Salient Pharmaceuticals; University of Texas M. D. Anderson Cancer Center
  • Class Aluminium compounds; Antidiarrhoeals; Calcium compounds; Noncarboxylic acids
  • Mechanism of Action Cytokine inhibitors; Interleukin 1 inhibitors; Interleukin 10 inhibitors; Interleukin 6 inhibitors; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Clostridium infections; Diarrhoea; Inflammatory bowel diseases; Proctitis; Stomatitis

Most Recent Events

  • 19 Apr 2016 No recent reports on development identified - Phase-II for Diarrhoea (Chemotherapy-induced) in USA (PO)
  • 19 Apr 2016 No recent reports on development identified - Preclinical for Clostridium infections in USA (PO)
  • 19 Apr 2016 No recent reports on development identified - Preclinical for Inflammatory bowel disease in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top